PDE4C anticorps (C-Term)

N° du produit ABIN2750931

Cet anticorps Lapin Polyclonal détecte spécifiquement PDE4C dans WB, ELISA, IF, IHC, IP, ICC et CM. Il présente une réactivité envers Humain, Souris et Rat et a été mentionné dans 9+ publications.

Aperçu rapide pour PDE4C anticorps (C-Term) (ABIN2750931)

Antigène: PDE4C (phosphodiesterase 4C, CAMP-Specific (PDE4C))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PDE4C est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC), Confocal Microscopy (CM)

Détail du produit anti-PDE4C anticorps

Épitope: C-Term

Purification: Affinity Purified

Immunogène: Synthetic cyclic carboxy-terminal peptide common to all PDE4C variants.

Isotype: IgG

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.65 μg/μL

Références pour anticorps anti-PDE4C (ABIN2750931)

Cheng, Wu, He, Liu, Jia, Di, Ji: "siRNA-mediated silencing of phosphodiesterase 4B expression affects the production of cytokines in endotoxin-stimulated primary cultured microglia." dans: Experimental and therapeutic medicine, Vol. 12, Issue 4, pp. 2257-2264, (2017) (PubMed).

Ji, Di, He, Liu, Liu, Li, Zhang: "Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation." dans: Molecular medicine reports, Vol. 13, Issue 2, pp. 1914-22, (2016) (PubMed).

Massimi, Cardarelli, Galli, Giardi, Ragusa, Panera, Cinque, Cifone, Biagioni, Giorgi: "Increase of Intracellular Cyclic AMP by PDE4 Inhibitors Affects HepG2 Cell Cycle Progression and Survival." dans: Journal of cellular biochemistry, Vol. 118, Issue 6, pp. 1401-1411, (2016) (PubMed).

Petersen, Kristensen, Jeppesen, Grøndahl, Wissing, Macklon, Andersen: "Distribution and function of 3',5'-Cyclic-AMP phosphodiesterases in the human ovary." dans: Molecular and cellular endocrinology, Vol. 403, pp. 10-20, (2015) (PubMed).

Yougbaré, Boire, Roy, Lugnier, Rouseau: "NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production." dans: Canadian journal of physiology and pharmacology, Vol. 91, Issue 5, pp. 353-61, (2014) (PubMed).

Abusnina, Alhosin, Keravis, Muller, Fuhrmann, Bronner, Lugnier: "Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis." dans: Cellular signalling, Vol. 23, Issue 1, pp. 152-60, (2011) (PubMed).

Yougbare, Morin, Senouvo, Sirois, Albadine, Lugnier, Rousseau: "NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues." dans: American journal of physiology. Lung cellular and molecular physiology, Vol. 301, Issue 4, pp. L441-50, (2011) (PubMed).

Murray, Patel, Suda, Zhang, Thistlethwaite, Yuan, Insel: "Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1." dans: American journal of physiology. Lung cellular and molecular physiology, Vol. 292, Issue 1, pp. L294-303, (2007) (PubMed).

Gallagher, Bacon, Odumeru, Gallagher, Fitzpatrick, Regan: "Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression." dans: Neurotoxicology and teratology, Vol. 26, Issue 1, pp. 73-81, (2004) (PubMed).

Détails sur PDE4C

Antigène: PDE4C (phosphodiesterase 4C, CAMP-Specific (PDE4C))

Autre désignation: PDE4C

UniProt: Q08493

Pathways: Negative Regulation of Hormone Secretion, cAMP Metabolic Process